The TRITON-3 trial randomized patients with metastatic castrate resistant prostate cancer failing doublets hormonal therapy in the CS setting with BRCA 1, BRCA 2 or ATM alterations to rucaparib vs. physicians’ choice. Here, ATM is linked to prostate carcinoma.